Feedback
Settings

Settings

Goto Application

1. WO2017189433 - COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES

PermaLink
Publication Number WO/2017/189433
Publication Date 02.11.2017
International Application No. PCT/US2017/029143
International Filing Date 24.04.2017
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61K 2039/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
54characterised by the route of administration
A61K 39/3955
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
3955against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 39/39558
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
39558against tumor tissues, cells, antigens
A61K 39/39591
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39591Stabilisation, fragmentation
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • MEDIMMUNE, LLC [US]/[US]
Inventors
  • DU, Jiali
  • SHAH, Ambarish
Agents
  • MENSAH, Kwame, N.
  • BRASLOW, Kimberly
  • ALBAN, Patrick
  • DISE, Rebecca, S.
  • CARROLL, Sahnnon
Priority Data
62/327,21425.04.2016US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
(FR) COMPOSITIONS COMPRENANT UNE CO-FORMULATION D'ANTICORPS ANTI-PD-L1 ET ANTI-CTLA-4
front page image
Abstract
(EN)
Provided herein are compositions comprising coformulation of anti-PD-Ll and anti-CTLA-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD-Ll antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided.
(FR)
La présente invention concerne des compositions comprenant une co-formulation d'anticorps anti-PD-L1 et anti-CTLA-4, ou des fragments de liaison d’antigène de ceux-ci, et des procédés de fabrication et d'utilisation de telles compositions. Dans différents aspects, l'invention concerne des co-formulations stables de l'anticorps anti-PD-L1 durvalumab (MEDI4736) et de l'anticorps anti-CTLA-4 trémélimumab.
Also published as
AR108317
AU2017257505
BR112018071287
CA3020893
CL2018-2998
CL2018002998
CN109069631
CO20180011195
EP3448428
ID2019/01435
IL262344
IN201817043501
JP2019514889
KR1020180135475
MX2018012651
MYPI 2018703898
RU2018140960
SG11201807474S
Latest bibliographic data on file with the International Bureau
# -